Brief: PharmaTher And Vitruvias Enter Into Collaboration Agreement For Commercialization Of KETARX In The U.S.
20/06/2023 12:14
June 20 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER AND VITRUVIAS ENTER INTO COLLABORATION
AGREEMENT FOR
COMMERCIALIZATION OF KETARX™ (RACEMIC KETAMINE) IN THE U.S.
Source text for Eikon: ID:nGNXbjpC2s
Further company coverage: PHRM.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application